What is Leerink Partnrs’ Forecast for Zymeworks Q1 Earnings?

Zymeworks Inc. (NYSE:ZYME) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.51) per share for the quarter. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

Several other brokerages also recently weighed in on ZYME. Citigroup boosted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, March 7th. HC Wainwright increased their price target on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, March 10th. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price for the company in a report on Monday, December 16th. Lifesci Capital assumed coverage on Zymeworks in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, Wells Fargo & Company upped their target price on shares of Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Zymeworks Stock Performance

Zymeworks stock opened at $12.93 on Thursday. The firm has a market capitalization of $899.63 million, a price-to-earnings ratio of -8.62 and a beta of 1.13. The stock’s fifty day moving average is $13.73 and its two-hundred day moving average is $13.67. Zymeworks has a fifty-two week low of $7.97 and a fifty-two week high of $17.70.

Institutional Investors Weigh In On Zymeworks

Several large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its position in Zymeworks by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock worth $1,667,000 after buying an additional 650 shares in the last quarter. Nuveen Asset Management LLC raised its position in shares of Zymeworks by 0.4% in the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock valued at $3,031,000 after acquiring an additional 886 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Zymeworks by 6.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock worth $214,000 after purchasing an additional 940 shares in the last quarter. Sterling Capital Management LLC grew its position in shares of Zymeworks by 781.5% in the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after purchasing an additional 1,524 shares during the period. Finally, FMR LLC increased its holdings in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after purchasing an additional 1,525 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Ecor1 Capital, Llc purchased 11,958 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The stock was bought at an average price of $14.12 per share, for a total transaction of $168,846.96. Following the purchase, the director now owns 14,704,239 shares in the company, valued at $207,623,854.68. The trade was a 0.08 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kenneth Galbraith sold 57,291 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $854,781.72. Following the completion of the transaction, the chief executive officer now owns 47,543 shares in the company, valued at $709,341.56. The trade was a 54.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have acquired 1,507,168 shares of company stock worth $19,339,774 and have sold 89,601 shares worth $1,336,847. 1.92% of the stock is currently owned by corporate insiders.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.